These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 12036933)
1. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Briones J; Timmerman J; Levy R Cancer Res; 2002 Jun; 62(11):3195-9. PubMed ID: 12036933 [TBL] [Abstract][Full Text] [Related]
2. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response. Alvarez E; Moga E; Barquinero J; Sierra J; Briones J Gene Ther; 2010 Apr; 17(4):469-77. PubMed ID: 20010627 [TBL] [Abstract][Full Text] [Related]
3. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector. Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669 [TBL] [Abstract][Full Text] [Related]
4. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Rieger R; Kipps TJ Cancer Res; 2003 Jul; 63(14):4128-35. PubMed ID: 12874017 [TBL] [Abstract][Full Text] [Related]
6. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Liu Y; Xia D; Li F; Zheng C; Xiang J Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183 [TBL] [Abstract][Full Text] [Related]
7. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458 [TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Noguchi M; Imaizumi K; Kawabe T; Wakayama H; Horio Y; Sekido Y; Hara T; Hashimoto N; Takahashi M; Shimokata K; Hasegawa Y Cancer Gene Ther; 2001 Jun; 8(6):421-9. PubMed ID: 11498762 [TBL] [Abstract][Full Text] [Related]
9. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Kikuchi T; Miyazawa N; Moore MA; Crystal RG Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803 [TBL] [Abstract][Full Text] [Related]
10. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. Guinn BA; DeBenedette MA; Watts TH; Berinstein NL J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049 [TBL] [Abstract][Full Text] [Related]
11. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318 [TBL] [Abstract][Full Text] [Related]
12. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Meziane el K; Bhattacharyya T; Armstrong AC; Qian C; Hawkins RE; Stern PL; Dermime S Int J Cancer; 2004 Oct; 111(6):910-20. PubMed ID: 15300803 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand. Liu A; Guardino A; Chinsangaram L; Goldstein MJ; Panicali D; Levy R Cancer Res; 2007 Jul; 67(14):7037-44. PubMed ID: 17638917 [TBL] [Abstract][Full Text] [Related]
14. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Todo T; Martuza RL; Dallman MJ; Rabkin SD Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154 [TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496 [TBL] [Abstract][Full Text] [Related]
16. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40. Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328 [TBL] [Abstract][Full Text] [Related]
17. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors. Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Ling X; Wang Y; Dietrich MF; Andreeff M; Arlinghaus RB Oncogene; 2006 Jul; 25(32):4483-90. PubMed ID: 16547503 [TBL] [Abstract][Full Text] [Related]
19. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793 [TBL] [Abstract][Full Text] [Related]
20. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]